Market Cap 1.35B
Revenue (ttm) 0.00
Net Income (ttm) -227.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.24
Volume 820,525
Avg Vol 1,050,604
Day's Range N/A - N/A
Shares Out 71.73M
Stochastic %K 43%
Beta 1.01
Analysts Strong Sell
Price Target $29.46

Company Profile

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerla...

Industry: Biotechnology
Sector: Healthcare
Phone: 41 415108022
Address:
Dorfstrasse 29, Zug, Switzerland
TradesTyrone
TradesTyrone May. 13 at 7:45 PM
$MLTX wen 60
0 · Reply
kuwoson
kuwoson May. 13 at 7:25 PM
$MLTX At what point will there be new buyout offers (assuming big pharma is seriously considering one)? I'm not familiar with the mechanisms for acquisitions in the pharmaceutical industry, but isn't there a risk for potential buyers that an acquisition will become increasingly expensive?
1 · Reply
Rockybhai7239
Rockybhai7239 May. 13 at 7:25 PM
$MLTX how can you miss blackrock 1M shares 256% increase
0 · Reply
EZ_Money11
EZ_Money11 May. 13 at 7:23 PM
$MLTX Who’s waiting for $25+ to sell a single share?? Charts building pressure and looks primed for a big move soon! 📈
1 · Reply
Bigbadjohn89
Bigbadjohn89 May. 13 at 6:24 PM
0 · Reply
LouKojak
LouKojak May. 13 at 5:49 PM
$MLTX JP Morgan big buy
6 · Reply
septrading
septrading May. 13 at 5:46 PM
$BMEA $MLTX are both priced like broken or half-credited stories, but their next datasets will force the market to re-rate them as platform companies overnight. For BMEA, credible early weight-loss from oral GLP-1 candidate BMF-650 would move it out of diabetes optionality and into the hottest obesity trade in biotech, while Icovamenib’s longer-dosing programs keeps the beta-cell regeneration story alive. For MLTX, 52-week VELA durability, adolescent HS confirmation in VELA-TEEN, and a clean IZAR-1 PsA win will turn Sonelokimab from a disputed HS asset into a multi-indication IL-17A/F franchise with BLA visibility, scarcity value, and obvious strategic appeal to immunology buyers. In both cases, the setup is explosive because the market is not paying for clean, compounding data; it is paying for skepticism — and when skepticism has to cover, triples happen fast. Know what you own.
0 · Reply
midas7576
midas7576 May. 13 at 5:19 PM
0 · Reply
Cardwizard
Cardwizard May. 13 at 4:46 PM
$MLTX finally the damn thing looks like it’s starting to climb. It’s about goddamn time. 
0 · Reply
AXMO
AXMO May. 13 at 4:41 PM
0 · Reply
Latest News on MLTX
MoonLake Immunotherapeutics management to meet with BTIG

2026-03-26T17:25:33.000Z - 6 weeks ago

MoonLake Immunotherapeutics management to meet with BTIG


MoonLake price target raised to $70 from $45 at Clear Street

2026-03-11T10:36:37.000Z - 2 months ago

MoonLake price target raised to $70 from $45 at Clear Street


MoonLake Immunotherapeutics Transcript: Investor Day 2026

Feb 23, 2026, 8:00 AM EST - 2 months ago

MoonLake Immunotherapeutics Transcript: Investor Day 2026


MoonLake announces results from Phase 2 trial of Sonelokimab

2026-02-22T19:15:48.000Z - 2 months ago

MoonLake announces results from Phase 2 trial of Sonelokimab


MoonLake price target raised to $32 from $26 at H.C. Wainwright

2026-01-09T11:15:53.000Z - 4 months ago

MoonLake price target raised to $32 from $26 at H.C. Wainwright


TradesTyrone
TradesTyrone May. 13 at 7:45 PM
$MLTX wen 60
0 · Reply
kuwoson
kuwoson May. 13 at 7:25 PM
$MLTX At what point will there be new buyout offers (assuming big pharma is seriously considering one)? I'm not familiar with the mechanisms for acquisitions in the pharmaceutical industry, but isn't there a risk for potential buyers that an acquisition will become increasingly expensive?
1 · Reply
Rockybhai7239
Rockybhai7239 May. 13 at 7:25 PM
$MLTX how can you miss blackrock 1M shares 256% increase
0 · Reply
EZ_Money11
EZ_Money11 May. 13 at 7:23 PM
$MLTX Who’s waiting for $25+ to sell a single share?? Charts building pressure and looks primed for a big move soon! 📈
1 · Reply
Bigbadjohn89
Bigbadjohn89 May. 13 at 6:24 PM
0 · Reply
LouKojak
LouKojak May. 13 at 5:49 PM
$MLTX JP Morgan big buy
6 · Reply
septrading
septrading May. 13 at 5:46 PM
$BMEA $MLTX are both priced like broken or half-credited stories, but their next datasets will force the market to re-rate them as platform companies overnight. For BMEA, credible early weight-loss from oral GLP-1 candidate BMF-650 would move it out of diabetes optionality and into the hottest obesity trade in biotech, while Icovamenib’s longer-dosing programs keeps the beta-cell regeneration story alive. For MLTX, 52-week VELA durability, adolescent HS confirmation in VELA-TEEN, and a clean IZAR-1 PsA win will turn Sonelokimab from a disputed HS asset into a multi-indication IL-17A/F franchise with BLA visibility, scarcity value, and obvious strategic appeal to immunology buyers. In both cases, the setup is explosive because the market is not paying for clean, compounding data; it is paying for skepticism — and when skepticism has to cover, triples happen fast. Know what you own.
0 · Reply
midas7576
midas7576 May. 13 at 5:19 PM
0 · Reply
Cardwizard
Cardwizard May. 13 at 4:46 PM
$MLTX finally the damn thing looks like it’s starting to climb. It’s about goddamn time. 
0 · Reply
AXMO
AXMO May. 13 at 4:41 PM
0 · Reply
Jkm11
Jkm11 May. 13 at 4:41 PM
0 · Reply
impossiblepub
impossiblepub May. 13 at 4:06 PM
0 · Reply
AXMO
AXMO May. 13 at 4:04 PM
0 · Reply
G_Ho
G_Ho May. 13 at 4:00 PM
0 · Reply
Obidagreat
Obidagreat May. 13 at 3:47 PM
0 · Reply
Bigbadjohn89
Bigbadjohn89 May. 13 at 3:33 PM
0 · Reply
sh3r1ock
sh3r1ock May. 13 at 3:24 PM
$MLTX me holding onto shares as the missed opportunity cost here keeps building
2 · Reply
Jkm11
Jkm11 May. 13 at 3:08 PM
$MLTX algos turned on. Probably nothing happening today.
0 · Reply
FlyingChemist01
FlyingChemist01 May. 13 at 3:01 PM
$MLTX I'll make it an example out of it too, when a substance is under investigation, and you get certain results, there is no doubt, there is no "well but maybe" once a substance gets classified (e.g. Bisphenol A for food contact) There is no coming back. Some producers even stopped using epoxy resins (source of possible BPA contaminants) and there are plenty plenty controls over the % of free BPA. This is a REAL example of FDA at work, they know that once they make that decision, the market will inevitably change. (imagine finding a suitable alternative, and maybe even a more expensive one to something that has been used for years!) yep, a whole industry looking for alternatives like a pack of maniacs. So back to the point, I don't think the FDA would allow such a claim if they were almost sure, or 100% sure about it. Because this claim is THE FIRST ever for a whole disease market, and that's just factual because they said it.
1 · Reply
Shaybe16569
Shaybe16569 May. 13 at 2:54 PM
$MLTX VERY good point from @FlyingChemist01 !
0 · Reply
FlyingChemist01
FlyingChemist01 May. 13 at 2:35 PM
$MLTX i actively work in the specialties chemicals industry in europe, i know a lot of things about regulatory affairs in my field (FDA and REACH). All i can say is that in my field the FDA regulations are extremely strict (such as food contact and so on). They usually tend to be extremely strict at pretty much everything. I still want to point out at the label decision. I think doing such a "Bold" move with such confidence clearly means they know something that we don't. I know this sounds extremely speculative but why would a regulatory federal angecy allow something if they are not extremely sure of the implications that could come? 43% HiSCR75, a literal new standard for HS and highest ever recorded.
3 · Reply
Shaybe16569
Shaybe16569 May. 13 at 2:18 PM
$MLTX @Cardwizard Biopharma isn’t traded like a normal company quarter-to-quarter. Stocks like MLTX trade around catalysts, data quality, and probability of future cash flows — not whether the chart was green for 3 days straight. The biggest returns in biotech usually come before broad recognition, while people are calling it “dead money.” If sonelokimab keeps delivering best-in-class durability, low ADA, strong efficacy across indications, and clean safety, the upside repricing can happen very fast because the market starts modeling blockbuster potential and/or buyout interest. People focusing on a few red days are watching the ticker. Long-term biotech investors are watching the data. If you don't have the patience, go invest in penny stocks!
5 · Reply